- Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
For: Non-Hodgkin LymphomaUnited States · China · Czechia - Active not recruitingPHASE1
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
This study is looking at a new medicine called epcoritamab for children and young adults (up to 25) with a type of Non-Hodgkin Lymphoma. It aims to see if the medicine is safe and how well it's tolerated when given by injection for lymphoma that has come back or hasn't responded to other treatments.
For: Non-hodgkin LymphomaUnited States · Australia · Belgium - RecruitingPHASE2
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
This study is testing a new drug, epcoritamab, for people in the UK with a type of brain lymphoma called PCNSL that has come back or not responded to previous treatments. It aims to see if adding epcoritamab to an existing treatment improves outcomes for patients.
For: Primary CNS Lymphoma (PCNSL)France - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
For: Follicular Lymphoma (FL)United States · Argentina · Australia - Active not recruitingPHASE2
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
This study looks at new treatments for a type of blood cancer called Diffuse Large B-Cell Lymphoma in older patients who can't have standard chemotherapy. It tests a drug called epcoritamab, with or without another drug called lenalidomide, to see how well they work and if they are safe.
For: Diffuse Large B-Cell LymphomaUnited States · Austria · Belgium - Active not recruitingPHASE3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
This study is testing a new medicine called epcoritamab for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. It aims to find the right dose, understand side effects, and see how well it works.
For: DLBCL · High-grade B-cell Lymphoma (HGBCL) · Primary Mediastinal Large B-cell Lymphoma (PMBCL)United States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
This study is looking into a new treatment, BMS-986458, both on its own and mixed with other anti-lymphoma medicines. It's for people in the UK with non-Hodgkin lymphoma that has come back or not responded to previous treatments. We want to see if it's safe and how well it works.
For: Relapsed/Refractory Non-Hodgkin LymphomaUnited States · Chile · China - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - Active not recruitingPHASE1, PHASE2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.
For: Diffuse Large B-Cell Lymphoma · Follicular LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria